Shopping Cart 0
Cart Subtotal
USD 0

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 1995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 5985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-China

Summary

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

The Chinese pharmaceutical industry-comprising the manufacturing of Western Medicines, Active Pharmaceutical Ingredients (API), Traditional Chinese Medicine (TCM), Biologics and Herbal Medicines-was valued at USD 168.6 billion in 2010 and grew to USD 424.6 billion in 2016. In 2010, the pharmaceutical market for western medicine was worth USD 53.8 billion, which increased to USD 106 billion in 2016 at a CAGR of 12%. It is forecast to be USD 132.9 billion in 2018 and reach USD 209 billion by 2022. The Chinese medical device market was valued at USD 36 billion in 2015, which increased to USD 40.1 billion in 2017. Since 2015, the China Food and Drug Administration (CFDA) has released several policies to reform the pharmaceutical market. Reforms to clinical trial processes have helped to reduce R&D costs and time, while initiatives for the market authorization process have helped to minimize regulatory delays.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the China, and includes-

- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

- Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Merck, Novartis, Jiangsu Hengrui Medicine, Sinopharm and Tong Ren Tang) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Boston Scientific and Shinva)

- Detailed analysis about recent completed deals in the pharmaceutical and medical device market of China

- Porter's five forces analysis for pharmaceutical and medical devices market of China

- An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices

- Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure

- An overview of the opportunities for and challenges to growth in the Chinese healthcare market.

Reasons to buy

This report will enhance your decision-making capability by allowing you to-

- Develop business strategies by understanding the trends shaping and driving the Chinese healthcare market

- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future

- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors

- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

- Identify, understand, and capitalize on the opportunities and challenges in the Chinese healthcare market.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Overview of Ph

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

China, Pharmaceutical Market, Medical Devices, Drivers and Barriers, Major Players, Regulatory landscape, Reimbursement landscape, Deals, Porter Five Forces, Opportunities and Challenges

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-China

Summary

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape-China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

The Chinese pharmaceutical industry-comprising the manufacturing of Western Medicines, Active Pharmaceutical Ingredients (API), Traditional Chinese Medicine (TCM), Biologics and Herbal Medicines-was valued at USD 168.6 billion in 2010 and grew to USD 424.6 billion in 2016. In 2010, the pharmaceutical market for western medicine was worth USD 53.8 billion, which increased to USD 106 billion in 2016 at a CAGR of 12%. It is forecast to be USD 132.9 billion in 2018 and reach USD 209 billion by 2022. The Chinese medical device market was valued at USD 36 billion in 2015, which increased to USD 40.1 billion in 2017. Since 2015, the China Food and Drug Administration (CFDA) has released several policies to reform the pharmaceutical market. Reforms to clinical trial processes have helped to reduce R&D costs and time, while initiatives for the market authorization process have helped to minimize regulatory delays.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the China, and includes-

- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

- Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Merck, Novartis, Jiangsu Hengrui Medicine, Sinopharm and Tong Ren Tang) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Boston Scientific and Shinva)

- Detailed analysis about recent completed deals in the pharmaceutical and medical device market of China

- Porter's five forces analysis for pharmaceutical and medical devices market of China

- An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices

- Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure

- An overview of the opportunities for and challenges to growth in the Chinese healthcare market.

Reasons to buy

This report will enhance your decision-making capability by allowing you to-

- Develop business strategies by understanding the trends shaping and driving the Chinese healthcare market

- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future

- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors

- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

- Identify, understand, and capitalize on the opportunities and challenges in the Chinese healthcare market.

READ MORE

Scope

Table of Contents

Executive Summary

Overview of Ph

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

China, Pharmaceutical Market, Medical Devices, Drivers and Barriers, Major Players, Regulatory landscape, Reimbursement landscape, Deals, Porter Five Forces, Opportunities and Challenges